KRAS gene amplification is a distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined RAS/RAF/MEK/ERK and PI3K/PTEN/AKT/mTOR pathway inhibition

被引：0
|
作者：
Henderson, Les [1 ]
Xu, Peng [1 ]
Rambo, Brittany [1 ]
Liao, Wei-Li [2 ]
Hembrough, Todd [2 ]
Catenacci, Daniel [1 ]
机构：
[1] Univ Chicago Med, Chicago, IL USA
[2] Oncoplex Dx Inc, Rockville, MD USA
来源：
MOLECULAR CANCER RESEARCH | 2014年 / 12卷
关键词：
D O I：
10.1158/1557-3125.RASONC14-A55
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A55
引用
收藏
页数：2
相关论文
共 37 条
  • [1] Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
    Butler, Dominika E.
    Marlein, Christopher
    Walker, Hannah F.
    Frame, Fiona M.
    Mann, Vincent M.
    Simms, Matthew S.
    Davies, Barry R.
    Collins, Anne T.
    Maitland, Norman J.
    ONCOTARGET, 2017, 8 (34) : 56698 - 56713
  • [2] Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
    Chappell, William H.
    Steelman, Linda S.
    Long, Jacquelyn M.
    Kempf, Ruth C.
    Abrams, Stephen L.
    Franklin, Richard A.
    Baesecke, Joerg
    Stivala, Franca
    Donia, Marco
    Fagone, Paolo
    Malaponte, Graziella
    Mazzarino, Maria C.
    Nicoletti, Ferdinando
    Libra, Massimo
    Maksimovic-Ivanic, Danijela
    Mijatovic, Sanja
    Montalto, Giuseppe
    Cervello, Melchiorre
    Laidler, Piotr
    Milella, Michele
    Tafuri, Agostino
    Bonati, Antonio
    Evangelisti, Camilla
    Cocco, Lucio
    Martelli, Alberto M.
    McCubrey, James A.
    ONCOTARGET, 2011, 2 (03) : 135 - 164
  • [3] Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
    Steelman, L. S.
    Abrams, S. L.
    Whelan, J.
    Bertrand, F. E.
    Ludwig, D. E.
    Baesecke, J.
    Libra, M.
    Stivala, F.
    Milella, M.
    Tafuri, A.
    Lunghi, P.
    Bonati, A.
    Martelli, A. M.
    McCubrey, J. A.
    LEUKEMIA, 2008, 22 (04) : 686 - 707
  • [4] Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
    L S Steelman
    S L Abrams
    J Whelan
    F E Bertrand
    D E Ludwig
    J Bäsecke
    M Libra
    F Stivala
    M Milella
    A Tafuri
    P Lunghi
    A Bonati
    A M Martelli
    J A McCubrey
    Leukemia, 2008, 22 : 686 - 707
  • [5] RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
    Yajima, Ichiro
    Kumasaka, Mayuko Y.
    Nguyen Dinh Thang
    Goto, Yuji
    Takeda, Kozue
    Yamanoshita, Osamu
    Iida, Machiko
    Ohgami, Nobutaka
    Tamura, Haruka
    Kawamoto, Yoshiyuki
    Kato, Masashi
    DERMATOLOGY RESEARCH AND PRACTICE, 2012, 2012
  • [6] Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma
    Guenther, Monika Katharina
    Graab, Ulrike
    Fulda, Simone
    CANCER LETTERS, 2013, 337 (02) : 200 - 209
  • [7] Therapeutic Resistance Resulting From Mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Signaling Pathways
    McCubrey, James A.
    Steelman, Linda S.
    Kempf, C. Ruth
    Chappell, William H.
    Abrams, Stephen L.
    Stivala, Franca
    Malaponte, Graziella
    Nicoletti, Ferdinando
    Libra, Massimo
    Baesecke, Joerg
    Maksimovic-Ivanic, Danijela
    Mijatovic, Sanja
    Montalto, Giuseppe
    Cervello, Melchiorre
    Cocco, Lucio
    Martelli, Alberto M.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (11) : 2762 - 2781
  • [8] Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.
    McCubrey, James A.
    Steelman, Linda S.
    Chappell, William H.
    Abrams, Stephen L.
    Montalto, Giuseppe
    Cervello, Melchiorre
    Nicoletti, Ferdinando
    Fagone, Paolo
    Malaponte, Grazia
    Mazzarino, Maria C.
    Candido, Saverio
    Libra, Massimo
    Baesecke, Joerg
    Mijatovic, Sanja
    Maksimovic-Ivanic, Danijela
    Milella, Michele
    Tafuri, Agostino
    Cocco, Lucio
    Evangelisti, Camilla
    Chiarini, Francesca
    Martelli, Alberto M.
    ONCOTARGET, 2012, 3 (09) : 954 - 987
  • [9] PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives
    Asati, Vivek
    Mahapatra, Debarshi Kar
    Bharti, Sanjay Kumar
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 109 : 314 - 341
  • [10] Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
    J A McCubrey
    L S Steelman
    S L Abrams
    F E Bertrand
    D E Ludwig
    J Bäsecke
    M Libra
    F Stivala
    M Milella
    A Tafuri
    P Lunghi
    A Bonati
    A M Martelli
    Leukemia, 2008, 22 : 708 - 722
1234